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GENERAL CONSIDERATIONS
Systemic hypertension is the most common cardiovascular
condition observed in competitive athletes. The diagnosis of
hypertension is based on the presence of blood pressure
(BP) persistently at or above certain levels as measured by
routine sphygmomanometry on at least two separate occa-
sions. A level above 140/90 mm Hg is considered to be
hypertensive in people over age 18 years (1). In children and
adolescents, hypertension is defined as average systolic or
diastolic levels greater than or equal to the 95th percentile
for gender, age, and height (2). In determining the level of
competitive athletic activity that a hypertensive person may
assume, it is also important to ascertain the degree of
hypertension-related target organ damage. Although hyper-
tension may be associated with an increased risk for complex
ventricular arrhythmias and sudden death, this disease by
itself has not been incriminated as a cause of sudden cardiac
death in young competitive athletes (3). For the general
population, increased levels of noncompetitive physical ac-
tivity are regarded not only as beneficial by reducing BP (4)
and the incidence of hypertension (5), but also protect-
ing against stroke (6). In view of the striking increase in
obesity-induced hypertension among children and adoles-
cents related in part to physical inactivity, all people should
be encouraged to engage in regular exercise. Those who are
hypertensive derive protection from all-cause and cardiovas-
cular mortality by maintaining higher levels of cardiorespi-
ratory fitness (7).
Assessment of blood pressure. Blood pressure should be
accurately measured in all individuals who wish to partici-
pate in competitive athletics before they begin training.
Blood pressure should be measured by routine sphygmoma-
nometry, using the guidelines listed in Table 1 (8). There
are often “white-coat” elevations induced by anxiety related
to the examination, particularly in young people concerned
about the potential consequences of the examination.
Therefore, additional BP recordings outside the office
should be obtained in those with elevated office readings,
either with readily available and inexpensive home self-
recorders or with less accessible and more expensive auto-
matic ambulatory monitors.
Evaluation. Those individuals with any degree of persis-
tent hypertension should have a thorough history and
physical examination and limited laboratory testing to
evaluate secondary causes and to ascertain target organ
damage (1). If agents that may raise BP such as non-
steroidal anti-inflammatory drugs (NSAIDs) are being
taken, additional measurements should be obtained after
they have been discontinued. Laboratory testing for most
subjects with stage 1 hypertension (140 to 159 mm Hg/
90 to 99 mm Hg) should include an automated blood chem-
istry (glucose, creatinine, or the corresponding estimated glo-
merular filtration rate, electrolytes, lipid profile), hematocrit,
urine analysis, and an electrocardiogram. If hypertension is
stage 2 (greater than or equal to 160/100 mm Hg), if results of
the initial laboratory tests are abnormal, or if features suggestive
of identifiable (secondary) causes are noted by history or
physical examination, the patient should be referred for addi-
tional study (including echocardiography) and therapy.
Effects of exercise on BP. As noted during stress testing,
systolic BP rises during aerobic (dynamic) exercise. Both
systolic and diastolic pressures rise even more acutely and to
higher levels during resistance (static or isometric) exercise.
Because strenuous aerobic or resistance exertion may pre-
cipitate myocardial infarction and sudden death in suscep-
tible, untrained individuals (9), those individuals who wish
to engage in competitive athletics should increase exercise
levels gradually to avoid such cardiac catastrophes.
However, repetitive performance of both aerobic and resis-
tance exercise lowers systolic and diastolic BP (4,10). After
each 30-min period of aerobic exercise at 50% of maximal
oxygen uptake, the blood pressure remains lower for up to 24 h,
with an even greater reduction after 30 min of aerobic exercise
at 75% of maximal oxygen uptake (11). As a consequence, the
risks of developing elevated BP (5) and of incurring a cardio-
vascular consequence of hypertension (6,7) are less in those
who maintain higher levels of physical activity. Some condi-
tioned athletes (particularly young men), with a slow heart rate
and compensatory increase in stroke volume, have high systolic
BP that is considered “spurious” hypertension (12) but should
nevertheless be carefully monitored.
In normotensive untrained subjects, an excessive rise in
systolic BP to above 200 mm Hg during an exercise stress
test is predictive of a greater likelihood of the development
of persistent hypertension in the future and may be associ-
ated with subtle systolic dysfunction (13) and an increased
risk of subsequent cardiovascular disease (14). Therefore,
such subjects should be advised to increase levels of physical
activity gradually to moderate such excessive rises in pres-
sure. Such rises should not restrict activity in those who are
well conditioned. Because intensive resistive training may
reduce arterial compliance with potential adverse conse-
quences (15), such training should be limited in those
athletes with hypertension.
Effects of blood pressure on exercise. Untreated hyper-
tension in athletes may be accompanied by some limitation
in exercise performance (16). Before initiating drug therapy,
athletes should be strongly encouraged to adopt healthy
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lifestyle behavior and avoid tobacco in any form, excess
alcohol, drugs of abuse (especially sympathomimetics such
as cocaine or ephedra), androgens, steroids, growth hor-
mone, NSAIDs, and excessive sodium intake. It should be
emphasized that the use of antihypertensive drugs may
further limit exercise capacity, more so with beta-adrenergic
receptor blocking agents than with vasodilators (alpha-
adrenergic blocking agents, angiotensin-converting enzyme
inhibitors, angiotensin II-receptor blockers, or calcium
channel blockers). Indeed, high-intensity competitive ath-
letes may find it very difficult to perform satisfactorily while
using beta-blockers (17).
Recommendations:
1. Before individuals commence training for competi-
tive athletics, they should undergo careful assessment
of BP and those with initially high levels (above
140/90 mm Hg) should have out-of-office measure-
ments to exclude isolated office “white-coat” hyper-
tension. Those with pre-hypertension (120/80 mm
Hg up to 139/89 mm Hg) should be encouraged to
modify lifestyle but should not be restricted from
physical activity. Those with sustained hypertension
should have echocardiography. Left ventricular hy-
pertrophy (LVH) beyond that seen with “athletes’
heart” should limit participation until BP is normal-
ized by appropriate drug therapy.
2. The presence of stage 1 hypertension in the absence of
target organ damage including LVH or concomitant
heart disease should not limit the eligibility for any
competitive sport. Once having begun a training pro-
gram, the hypertensive athlete should have BP remea-
sured every two to four months (or more frequently, if
indicated) to monitor the impact of exercise.
3. Athletes with more severe hypertension (stage 2),
even without evidence of target organ damage such as
LVH, should be restricted, particularly from high
static sports (classes IIIA to IIIC), until their hyper-
tension is controlled by either lifestyle modification
or drug therapy.
4. All drugs being taken must be registered with appro-
priate governing bodies to obtain a therapeutic ex-
emption.
5. When hypertension coexists with another cardiovas-
cular disease, eligibility for participation in compet-
itive athletics is usually based on the type and severity
of the associated condition.
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Table 1. Guidelines for Blood Pressure Measurement
Posture
Blood pressure obtained in the seated position is recommended. The
subject should sit quietly for 5 min, with the back supported in a
chair, with feet on the floor, and the arm supported at the level
of the heart, before recording blood pressure.
Circumstances
No caffeine during the hour preceding the reading.
No smoking during the 30 min preceding the reading.
A quiet, warm setting.
Equipment
Cuff size
The bladder should encircle and cover at least 80% of the length of
the arm; if it does not, use a larger cuff. If bladder is too short,
misleadingly high readings may result.
Manometer
Use a mercury, recently calibrated aneroid, or validated electronic
device.
Technique
Number of readings
On each occasion, take at least two readings, separated by as much
time as is practical. If readings vary by greater than 5 mm Hg,
take additional readings until two consecutive readings are close.
If the arm pressure is elevated, take the measurement in one leg
(particularly in patients less than 30 years old).
Initially, take pressures in both arms; if the pressures differ, use the
arm with the higher pressure.
If the initial values are elevated, obtain two other sets of readings at
least 1 week apart.
Performance
Inflate the bladder quickly to a pressure 20 mm Hg above the
systolic pressure, as recognized by the disappearance of the radial
pulse.
Deflate the bladder 2 mm Hg per second.
Record the Korotkoff phase I (appearance) and phase V
(disappearance).
If the Korotkoff sounds are weak, have the patient raise the arm,
open and close the hand 5 to 10 times and then reinflate the
bladder quickly.
Recordings
Blood pressure, patient position, and arm and cuff size.
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ATHEROSCLEROTIC CORONARY ARTERY DISEASE
General considerations. Compelling evidence indicates
that physical activity reduces cardiovascular events in
healthy subjects and cardiac mortality in patients with
diagnosed coronary artery disease (CAD) (1). Despite these
beneficial exercise effects, vigorous physical activity also
transiently increases the risk of both acute myocardial
infarction (AMI) (2–4) and sudden cardiac death (SCD)
(5–7) with the greatest exercise risk among the most
habitually sedentary individuals (2,4,7).
Atherosclerotic CAD is the most frequent cause of these
exercise-related cardiac events in adults (8), variously defined as
older than 30, 35, or 40 years of age. Both plaque rupture
(9,10) and possibly plaque erosion (11) have been implicated as
the immediate cause of exercise-related events in adults, al-
though plaque rupture is more frequent. Several studies over
the last decade document that cardiac events frequently occur
in coronary arteries that were not previously critically narrowed.
This appears to be particularly true for exercise-related cardiac
events because angiographic studies of exercise-related AMI in
the general population (4) and in sport participants (10)
demonstrate less extensive CAD than in comparison subjects.
This observation may reflect either selection bias for less severe
atherosclerosis in those capable of exercising at high intensity
1348 Thompson et al. JACC Vol. 45, No. 8, 2005
Task Force 6: Coronary Artery Disease April 19, 2005:1348–53
